Tempus Raises 2026 Sales Range After Oncology Volume Accelerates

The Tip Desk · November 2, 2026 · 2 min read

Third-quarter revenue reached $411.5 million, up 23%, as Adjusted EBITDA widened to $25.6 million and full-year sales guidance moved to $1.60–$1.605 billion.

Tempus AI, Inc. (TEM), a technology company applying artificial intelligence to precision medicine, reported third-quarter revenue of $411.5 million, up 23% from a year earlier, and raised its full-year 2026 sales outlook to $1.60 billion to $1.605 billion, which the company said represents about 25% annual growth.

The year-over-year sales increase followed 22% growth in the second quarter and 36.1% growth in the first quarter. Founder and Chief Executive Eric Lefkofsky said the quarter was a record, citing accelerating oncology unit growth and momentum in Data & Applications.

Diagnostics generated $303.5 million, matching the 20% year-over-year growth rate reported in the second quarter. Oncology volume growth accelerated to 32% from 31% in the second quarter and 28% in the first. Hereditary revenue growth was 3%, down from 5% in the second quarter. Minimal Residual Disease volume was about 12,000 tests, up 300% year-over-year, after 9,000 tests in the second quarter and about 6,500 in the first.

Data and Applications contributed $108.1 million, up 33% year-over-year, after 28% growth in the second quarter. Insights, the data licensing and modeling line, grew 29%, down from 36% in the second quarter and 44.1% in the first. Gross profit was $266.7 million, up 27%, after 26% growth in the second quarter.

Adjusted EBITDA was $25.6 million, compared with $8.0 million in the second quarter and a loss of $2.8 million in the first quarter. The GAAP net loss was $14.9 million, or $0.08 a share, after net income of $5.6 million in the second quarter. The third-quarter loss included $50.8 million of stock-based compensation and related employer payroll taxes and $42.8 million of unrealized gains on marketable securities.

Tempus ended September 30 with cash and marketable securities of $854.4 million, up from $820.7 million at June 30.

In October the company announced a collaboration with BMS to license oncology data and models for up to $137.5 million over five years, plus a $55 million five-year Alzheimer’s and dementia data license with BMS and Pathos. Tempus said those deals brought total data licensing bookings to more than $550 million year to date. It also announced a multi-year collaboration with Merck and Moderna to support commercialization of an individualized neoantigen therapy.

Regulatory review of the pending acquisition of Personalis was cleared, with a shareholder meeting planned for November 30, 2026. The company also received two FDA 510(k) clearances for Tempus ECG-PH and ECG-MR and announced an initiative to build a research platform of 100,000 whole genomes linked to longitudinal clinical information.

Full-year Adjusted EBITDA guidance remained about $65 million.